Dr. Matthew Johnson on Huberman Lab: How Psilocybin Heals

The term “psychedelic” spans several pharmacological classes, so it is more a high‑level functional or cultural term than a precise pharmacological one. Across classic 5‑HT2A agonists (LSD, psilocybin, DMT, mescaline), NMDA antagonists (ketamine, PCP, dextromethorphan), and MDMA, the common denominator is the ability to profoundly alter one’s sense of reality and sense of self. This ‘model-dissolving’ property is what makes these substances both powerful therapeutically and potentially destabilizing.

Johnson emphasizes that the most compelling clinical outcomes come from ‘heroic doses’ of psilocybin (around 20–30 mg of pure psilocybin) administered in a controlled setting with extensive preparation and integration, not from casual or task‑filled sessions. These high‑dose sessions, framed inside a safe relational container with trained guides, allow participants to fully enter and explore intense emotional and perceptual states. One to three such sessions can yield months‑to‑year‑long improvements in depression, addiction, and cancer-related anxiety when combined with proper therapeutic support.

Across disorders like depression and nicotine addiction, Johnson observes that when treatment works best, people undergo a deep shift in how they represent themselves: from ‘I am a depressed person’ or ‘I am a smoker who can’t quit’ to an identity with more agency and possibility. These are often described as ‘duh’ realizations—ideas they already intellectually knew but now embody with powerful emotional conviction (‘I can just decide not to smoke’ or ‘I am causing most of my own suffering’). Psychedelics seem to temporarily relax rigid self-models, enabling profound reorganization and reconsolidation of memories and beliefs.

Intense psychedelic experiences often involve a sense of reality and self ‘shattering.’ Johnson suggests that this experiential threshold is the same doorway that can lead either to terrifying ‘bad trips’ or to transcendent, mystical-type experiences characterized by unity and positive long‑term outcomes. The critical variable is how the person responds in the moment: surrendering and letting go into the experience vs. fighting to maintain control and a familiar sense of self. Skilled guides, preparation, and reassurance (e.g., around physical safety) are crucial to help people move from panic toward surrender.

Psychedelics are not benign wellness tools; they can be profoundly destabilizing. People with psychotic disorders such as schizophrenia or bipolar mania are screened out of clinical trials because of concerns that psychedelics may worsen or trigger severe psychosis. Even in optimal, well‑prepared clinical environments and with psychologically healthy people, about one-third of participants at high psilocybin doses will experience a period of strong fear, anxiety, or feeling they are going insane or dying. Outside controlled settings, these reactions—combined with unsafe environments (e.g., navigating a city street)—can become dangerous.